BRIEF-Summit Says It Raised $200 Million And Expands License Territories For Ivonescimab

Reuters06-03

June 3 (Reuters) - Summit Therapeutics Inc :

* SUMMIT RAISES $200 MILLION; ALSO EXPANDS LICENSE TERRITORIES FOR IVONESCIMAB

* SUMMIT THERAPEUTICS - EXPANDED LICENSE TERRITORIES FOR IVONESCIMAB IN DEAL WITH AKESO TO INCLUDE LATIN AMERICA, MIDEAST, AND AFRICA

* SUMMIT THERAPEUTICS - RECEIVED & ACCEPTED UNSOLICITED OFFER FROM INSTITUTIONAL INVESTOR TO PURCHASE 22.2 MILLION SHARES OF CO'S COMMON STOCK AT $9.00 PER SHARE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2440457942?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-03 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2440457942","market":"us","top_or_hot":-1,"title":"BRIEF-Summit Says It Raised $200 Million And Expands License Territories For Ivonescimab","media":"Reuters","content":"<html><body><p>June 3 (Reuters) - Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * SUMMIT RAISES $200 MILLION; ALSO EXPANDS LICENSE TERRITORIES FOR IVONESCIMAB</p><p>   * SUMMIT THERAPEUTICS - EXPANDED LICENSE TERRITORIES FOR IVONESCIMAB IN DEAL WITH AKESO TO INCLUDE LATIN AMERICA, MIDEAST, AND AFRICA</p><p>   * SUMMIT THERAPEUTICS - RECEIVED &amp; ACCEPTED UNSOLICITED OFFER FROM INSTITUTIONAL INVESTOR TO PURCHASE 22.2 MILLION SHARES OF CO'S COMMON STOCK AT $9.00 PER SHARE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Summit Says It Raised $200 Million And Expands License Territories For Ivonescimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Summit Says It Raised $200 Million And Expands License Territories For Ivonescimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-03 17:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 3 (Reuters) - Summit Therapeutics Inc   :   * SUMMIT RAISES $200 MILLION; ALSO EXPANDS LICENSE TERRITORIES FOR IVONESCIMAB   * SUMMIT THERAPEUTICS - EXPANDED LICENSE TERRITORIES FOR IVONESCIMAB ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2440457942","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440457942","pubTimestamp":1717407155,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"June 3  - Summit Therapeutics Inc   :   * SUMMIT RAISES $200 MILLION; ALSO EXPANDS LICENSE TERRITORIES FOR IVONESCIMAB   * SUMMIT THERAPEUTICS - EXPANDED LICENSE TERRITORIES FOR IVONESCIMAB IN DEAL WITH AKESO TO INCLUDE LATIN AMERICA, MIDEAST, AND AFRICA   * SUMMIT THERAPEUTICS - RECEIVED & ACCEPTED UNSOLICITED OFFER FROM INSTITUTIONAL INVESTOR TO PURCHASE 22.2 MILLION SHARES OF CO'S COMMON STOCK AT $9.00 PER SHARESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC","BK4211":"区域性银行","SMMF":"Summit Financial Group","BK4139":"生物科技"},"translate_title":"BRIEF-Summit表示已筹集2亿美元并扩大Ivonescimab的许可范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMF":1,"SMMT":0.9},"content_text":"June 3 (Reuters) - Summit Therapeutics Inc   :   * SUMMIT RAISES $200 MILLION; ALSO EXPANDS LICENSE TERRITORIES FOR IVONESCIMAB   * SUMMIT THERAPEUTICS - EXPANDED LICENSE TERRITORIES FOR IVONESCIMAB IN DEAL WITH AKESO TO INCLUDE LATIN AMERICA, MIDEAST, AND AFRICA   * SUMMIT THERAPEUTICS - RECEIVED & ACCEPTED UNSOLICITED OFFER FROM INSTITUTIONAL INVESTOR TO PURCHASE 22.2 MILLION SHARES OF CO'S COMMON STOCK AT $9.00 PER SHARESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440457942"}